Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8897336 | 1.00 | ALDH1A1 (0.33) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL8947056 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL8947051 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL13698843 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL25971659 | 0.67 | — | — | |
| SCHEMBL20109314 | 0.67 | KDM4E (0.30) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL19367682 | 0.67 | KDM4E (0.30) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL25971758 | 0.66 | GAA (0.30) | GAAPKMTDP1 | |
| SCHEMBL25971787 | 0.66 | GAA (0.30) | GAAPKMTDP1 | |
| SCHEMBL25971812 | 0.66 | GAA (0.30) | GAAPKMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633403-B2 | N-heterocyclic phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-09-21 | — | — | US | disclosed |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-09-21 | — | — | US | disclosed |
| US-5618964-A | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | ALDH1A1 4621/4885KDM4E 3603/4885HSD17B10 4053/4885 |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | ALDH1A1 4739/4885KDM4E 3835/4885HSD17B10 4619/4885 |
| US-10633403-B2 | N-heterocyclic phosphines | NANP, PPIP5K2, PHPT1 | ALDH1A1 4621/4885KDM4E 3603/4885HSD17B10 4053/4885 |
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | ALDH1A1 4739/4885KDM4E 3835/4885HSD17B10 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.